PHMMF (Pharma Mar) Notes Receivable : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Pharma Mar Notes Receivable?

Pharma Mar's Notes Receivable for the quarter that ended in Sep. 2024 was $0.0 Mil.

Pharma Mar Notes Receivable Historical Data

The historical data trend for Pharma Mar's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Notes Receivable Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Pharma Mar Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Pharma Mar Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Pharma Mar Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (OTCPK:PHMMF) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

PHMe:UK 0RC6:UK PHM:Spain

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.